Tegaserod is an aminoguanidine indole compound and a member of a new class of 5-hydroxytryptamine (5-HT) agonists. Activation of 5-HT4 receptors triggers the release of neurotransmitters from the enteric nerves which in turn stimulate contractility and peristalsis. This study will investigate the efficacy and safety of tegaserod against chronic constipation in a Chinese population of adult men and women

Condition	Intervention	Phase
Chronic constipation	Drug: Tegaserod	Phase III

Further Study Details: 

Ages Eligible for Study:  18 Years and above,  Genders Eligible for Study:  Both

Criteria

Inclusion Criteria:

• Men or women at least 18 years of age • History of constipation for at least 6 months prior to screening • Normal bowel evaluation performed within the past 5 years

Exclusion Criteria:

• Most bothersome symptom in last 6 months is abdominal pain/discomfort • Whose chronic constipation is thought to be a result of bowel surgery, gynecological surgery, neurologic disorder, systemic sclerosis, amyloidosis, scleroderma, myotonic dystrophy • Insulin dependent diabetes • Evidence of cathartic colon or laxative abuse

Please refer to this study by ClinicalTrials.gov identifier  NCT00139568

Novartis      +41 61 324  Ext. 1111 

Switzerland
      Novartis, Basel,  4056,  Switzerland; Recruiting

Study chairs or principal investigators

Novartis,  Study Chair,  Novartis Basel, Switzerland   

Study ID Numbers:  CHTF919E2308
Last Updated:  August 30, 2005
Record first received:  August 30, 2005
ClinicalTrials.gov Identifier:  NCT00139568
Health Authority: China: State Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-09-06